Diabetic retinopathy is a retinal microvascular disease that often causes blindness in adults who have had diabetes mellitus for 10 years or more. Estimates are that 600 million people will have some sort of diabetic retinopathy by 2040. Previously, no good animal models existed that scientists could use to study the disease, its diagnosis or potential treatments. Now, a team of researchers led by the University of Missouri has employed a mouse model exhibiting diabetic retinopathy symptoms that could lead to future translational research studies.
“Diabetic retinopathy is a common retinal complication of diabetes mellitus that can be categorized in different stages in humans,” said Shyam Chaurasia, an assistant professor of ophthalmology and vision sciences research in the MU College of Veterinary Medicine. “Multiple interlinked pathways—including malfunctions in the immune system—lead to cellular damage. These vascular and neuronal abnormalities in the retina lead to ‘blind spots’ and complete blindness. With the prevalence of diabetes reaching record levels, it is important to develop the tools needed to combat this disease.”
The team focused on a specific inflammasome, a protein responsible for the activation of inflammatory responses, called the NLRP3 inflammasome. Long-term hyperglycemia results in the activation of the NLRP3 inflammasome causing vascular leakages in the retina and eventually leading to neovascularization, which is the formation of new blood vessels or networks in the retina.
Using advanced retinal imaging techniques, the scientists tested these diabetic mice that processed NLRP3. Using a new technique called laser speckle flowgraphy, the group was able to create the “heat map” of blood flow volume and found significantly decreased levels in the NLRP3 mice. These mice also showed an increased prevalence of a buildup of macrophages in the retina that could be caused by immune responses involved in chronic inflammation that leads to diabetic retinopathy.
“Several new techniques and potential diagnostics are demonstrated in this study for the first time, including the laser speckle flowgraphy technique, which may prove useful in the diagnosis of human DR,” Chaurasia said. “This is the first study to show that the activation of the NLRP3 inflammasome is involved in the proliferative changes observed during DR progression, proving that this mouse model could be useful in screening potential drugs to fight the disease.”
The study, “The NLRP3 Inflammasome May Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic Retinopathy,” was published in Scientific Reports. Major funding was provided by Department of Veterinary Medicine and Surgery Start-up grant to Dr. Chaurasia. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Story Contact: Jeff Sossamon, sossamonj@missouri.edu, 573-882-3346
The MU College of Veterinary Medicine is Missouri’s only institution that confers the Doctor of Veterinary Medicine degree. Thank you for exploring how you can partner with us to make a positive difference in the lives of animals and people.